REFERENCES
2. Zhang X, Xu H, Li GH, et al. Metabolomics insights into osteoporosis through association with bone mineral density. J Bone Miner Res. 2021;36:729-38.
3. Shevroja E, Reginster JY, Lamy O, et al. Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging. Osteoporos Int. 2023;34:1501-29.
4. Ndumele CE, Neeland IJ, Tuttle KR, et al. ; American Heart Association. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the american heart association. Circulation. 2023;148:1636-64.
5. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148:1606-35.
6. Ye S, Shi L, Zhang Z. Effect of insulin resistance on gonadotropin and bone mineral density in nondiabetic postmenopausal women. Front Endocrinol. 2023;14:1235102.
7. Rodríguez-Gómez I, Gray SR, Ho FK, et al. Osteoporosis and its association with cardiovascular disease, respiratory disease, and cancer: findings from the UK Biobank prospective cohort study. Mayo Clin Proc. 2022;97:110-21.
8. Miller PD, Adachi JD, Albergaria BH, et al. Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Res. 2022;37:1437-45.
9. Zhang Y, Tan C, Tan W. BMI, socioeconomic status, and bone mineral density in U.S. adults: mediation analysis in the NHANES. Front Nutr. 2023;10:1132234.
10. Greere D, Grigorescu F, Manda D, et al. Relative contribution of metabolic syndrome components in relation to obesity and insulin resistance in postmenopausal osteoporosis. J Clin Med. 2024;13:2529.
11. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105:S117-314.
12. Inker LA, Eneanya ND, Coresh J, et al. ; Chronic Kidney Disease Epidemiology Collaboration. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385:1737-49.
13. Delbari N, Rajaei A, Oroei M, Ahmadzadeh A, Farsad F. A comparison between femoral neck and LS-BMD with LS-TBS in T2DM patients: a case control study. BMC Musculoskelet Disord. 2021;22:582.
14. Leslie WD, Binkley N, Schousboe JT, Silva BC, Hans D. Effect of abdominal tissue thickness on trabecular bone score and fracture risk in adults with diabetes: the Manitoba BMD registry. J Bone Miner Res. 2024;39:877-84.
15. Fazullina ON, Korbut AI, Klimontov VV. Factors associated with trabecular bone score in postmenopausal women with type 2 diabetes and normal bone mineral density. World J Diabetes. 2022;13:553-65.
16. Vigevano F, Gregori G, Colleluori G, et al. In men with obesity, T2DM is associated with poor trabecular microarchitecture and bone strength and low bone turnover. J Clin Endocrinol Metab. 2021;106:1362-76.
17. Wu B, Wu H, Wang Z, et al. Assessment of bone health in pre-dialysis CKD patients based on TBS reference range for the Chinese population. Front Med. 2025;12:1556782.
18. Aleksova J, Kurniawan S, Elder GJ. The trabecular bone score is associated with bone mineral density, markers of bone turnover and prevalent fracture in patients with end stage kidney disease. Osteoporos Int. 2018;29:1447-55.
19. Aleksova J, Kurniawan S, Vucak-Dzumhur M, et al. Aortic vascular calcification is inversely associated with the trabecular bone score in patients receiving dialysis. Bone. 2018;113:118-23.
20. Ciceri P, Cozzolino M. The emerging role of iron in heart failure and vascular calcification in CKD. Clin Kidney J. 2021;14:739-45.
21. Huang JF, Zheng XQ, Sun XL, et al. Association between bone mineral density and severity of chronic kidney disease. Int J Endocrinol. 2020;2020:8852690.
22. Tang H, He JH, Gu HB, et al. The different correlations between obesity and osteoporosis after adjustment of static mechanical loading from weight and fat free mass. J Musculoskelet Neuronal Interact. 2021;21:351-7.
23. Sheu A, Blank RD, Tran T, et al. Associations of type 2 diabetes, body composition, and insulin resistance with bone parameters: the dubbo osteoporosis epidemiology study. JBMR Plus. 2023;7:e10780.
24. Massy ZA, Drueke TB. Combination of cardiovascular, kidney, and metabolic diseases in a syndrome named cardiovascular-kidney-metabolic, with new risk prediction equations. Kidney Int Rep. 2024;9:2608-18.
25. Gao C, Gao S, Zhao R, et al. Association between systemic immune-inflammation index and cardiovascular-kidney-metabolic syndrome. Sci Rep. 2024;14:19151.
26. Yu B, Wang CY. Osteoporosis and periodontal diseases - an update on their association and mechanistic links. Periodontol 2000. 2022;89:99-113.
27. Forte YS, Renovato-Martins M, Barja-Fidalgo C. Cellular and molecular mechanisms associating obesity to bone loss. Cells. 2023;12:521.
28. Tang Y, Peng B, Liu J, Liu Z, Xia Y, Geng B. Systemic immune-inflammation index and bone mineral density in postmenopausal women: a cross-sectional study of the national health and nutrition examination survey (NHANES) 2007-2018. Front Immunol. 2022;13:975400.
29. Tao H, Li W, Zhang W, et al. Urolithin A suppresses RANKL-induced osteoclastogenesis and postmenopausal osteoporosis by, suppresses inflammation and downstream NF-κB activated pyroptosis pathways. Pharmacol Res. 2021;174:105967.
30. Moreira CA, Barreto FC, Dempster DW. New insights on diabetes and bone metabolism. J Bras Nefrol. 2015;37:490-5.
31. Sheng N, Xing F, Wang J, et al. Recent progress in bone-repair strategies in diabetic conditions. Mater Today Bio. 2023;23:100835.
32. Wong SK, Mohamad NV, Jayusman PA, Ibrahim N’. A review on the crosstalk between insulin and Wnt/β-catenin signalling for bone health. Int J Mol Sci. 2023;24:12441.
33. Yuan Y, Duan R, Wu B, et al. Gene expression profiles and bioinformatics analysis of insulin-like growth factor-1 promotion of osteogenic differentiation. Mol Genet Genomic Med. 2019;7:e00921.
34. Malluche HH, Porter DS, Pienkowski D. Evaluating bone quality in patients with chronic kidney disease. Nat Rev Nephrol. 2013;9:671-80.
35. Kužmová Z, Kužma M, Gažová A, et al. Fibroblast growth factor 23 and klotho are associated with trabecular bone score but not bone mineral density in the early stages of chronic kidney disease: results of the cross-sectional study. Physiol Res. 2021;70:S43-51.
36. Fan Z, Wei X, Zhu X, et al. Correlation between soluble klotho and chronic kidney disease-mineral and bone disorder in chronic kidney disease: a meta-analysis. Sci Rep. 2024;14:4477.
37. Liu Y, Song CY, Wu SS, Liang QH, Yuan LQ, Liao EY. Novel adipokines and bone metabolism. Int J Endocrinol. 2013;2013:895045.
38. Deepika F, Bathina S, Armamento-Villareal R. Novel adipokines and their role in bone metabolism: a narrative review. Biomedicines. 2023;11:644.
39. Walsh JS, Vilaca T. Obesity, type 2 diabetes and bone in adults. Calcif Tissue Int. 2017;100:528-35.
40. Campagnaro LS, Carvalho AB, Pina PM, Watanabe R, Canziani MEF. Bone mass measurement by DXA should be interpreted with caution in the CKD population with vascular calcification. Bone Rep. 2022;16:101169.
41. Mazziotti G, Lania AG, Canalis E. Skeletal disorders associated with the growth hormone-insulin-like growth factor 1 axis. Nat Rev Endocrinol. 2022;18:353-65.
42. Wang J, Cui W. Decoding the diabetic bone paradox: how AGEs sabotage skeletal integrity. Cell Rep Med. 2024;5:101693.
43. Ubago-Guisado E, Moratalla-Aranda E, González-Salvatierra S, et al. Do patients with type 2 diabetes have impaired hip bone microstructure? A study using 3D modeling of hip dual-energy X-ray absorptiometry. Front Endocrinol. 2022;13:1069224.
44. Paul J, Devarapalli V, Johnson JT, et al. Do proximal hip geometry, trabecular microarchitecture, and prevalent vertebral fractures differ in postmenopausal women with type 2 diabetes mellitus? A cross-sectional study from a teaching hospital in southern India. Osteoporos Int. 2021;32:1585-93.
45. Sheehan KJ, Sobolev B, Chudyk A, Stephens T, Guy P. Patient and system factors of mortality after hip fracture: a scoping review. BMC Musculoskelet Disord. 2016;17:166.
46. Goto NA, Weststrate ACG, Oosterlaan FM, et al. The association between chronic kidney disease, falls, and fractures: a systematic review and meta-analysis. Osteoporos Int. 2020;31:13-29.
47. Laroche M, Pécourneau V, Blain H, et al. ; GRIO scientific committee. Osteoporosis and ischemic cardiovascular disease. Joint Bone Spine. 2017;84:427-32.
